Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals

Zaeck, Luca M.; Lamers, Mart M.; Verstrepen, Babs E.; Bestebroer, Theo M.; Royen, Martin E. van; Götz, Hannelore M; Shamier, Marc C.; Leeuwen, Leanne P. M. van; Schmitz, Katharina S.; Alblas, Kimberley; Efferen, Suzanne van; Bogers, Susanne; Scherbeijn, Sandra; Rimmelzwaan, Guus F.; Gorp, Eric C. M. Van; Koopmans, Marion; Haagmans, Bart L.; GeurtsvanKessel, Corine H.; Vries, Rory D. de

doi:10.1038/s41591-022-02090-w

articleNature MedicineOct 18, 2022HYBRID OA

Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals

LMLuca M. Zaeck MMMart M. Lamers BEBabs E. Verstrepen TMTheo M. Bestebroer MEMartin E. van Royen

Erasmus MC · GGD Rotterdam-Rijnmond · +2 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern. Modified vaccinia Ankara-Bavarian Nordic (MVA-BN, also known as Imvamune, JYNNEOS or Imvanex) is a third-generation smallpox vaccine that is authorized and in use as a vaccine against MPX. To date, there are no data showing MPX virus (MPXV)-neutralizing antibodies in vaccinated individuals nor vaccine efficacy against MPX. Here we show that MPXV-neutralizing antibodies can be detected after MPXV infection and after historic smallpox vaccination. However, a two-shot MVA-BN immunization series in non-primed individuals yields relatively low levels of MPXV-neutralizing antibodies. Dose-sparing of an…

Citation impact

255

total citations

FWCI: 17.92
Percentile: 100%
References: 18

Citations per year

Authors

19

Topics & keywords

Topics

Keywords

Monkeypox
Virology
Vaccination
Antibody
Neutralizing antibody
Medicine
Virus
Immunology

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.